Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma

Outcomes for marginal zone lymphoma (MZL) and follicular lymphoma (FL) remain suboptimal, owing to the limited number of approved agents and the incurable nature of the diseases. BGB-3111-AU-003 was a phase 1/2, open-label, multicenter, single-agent study of the selective Bruton’s tyrosine kinase in...

Descripción completa

Detalles Bibliográficos
Autores principales: Phillips, Tycel, Chan, Henry, Tam, Constantine S., Tedeschi, Alessandra, Johnston, Patrick, Oh, Sung Yong, Opat, Stephen, Eom, Hyeon-Seok, Allewelt, Heather, Stern, Jennifer C., Tan, Ziwen, Novotny, William, Huang, Jane, Trotman, Judith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198905/
https://www.ncbi.nlm.nih.gov/pubmed/35390135
http://dx.doi.org/10.1182/bloodadvances.2021006083

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198905/
https://www.ncbi.nlm.nih.gov/pubmed/35390135
http://dx.doi.org/10.1182/bloodadvances.2021006083

Ejemplares similares